Heart Transplantation Therapeutics Market by Product and Geography

Global Heart Transplantation Therapeutics Market: About this market
The heart transplantation therapeutics market analysis considers sales from immunosuppressants and supplementary medications products. Our study also finds the sales of heart transplantation therapeutics in Asia, Europe, North America, and ROW. In 2019, the immunosuppressants segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as mechanism of actions (MoA) of these drugs to treat and prevent organ rejection will play a significant role in the immunosuppressants segment to maintain its market position. Also, our global heart transplantation therapeutics market report looks at factors such as rising prevalence of cardiovascular diseases and heart failures, availability of drugs in multiple dosage forms, and high dependency of immunosuppressants for heart transplantation. However, adverse effects of immunosuppressants, demand-supply imbalance for organ transplantation, and long-term complications associated with heart transplantation may hamper the growth of the heart transplantation therapeutics industry over the forecast period.

Global Heart Transplantation Therapeutics Market: Overview

High dependency on immunosuppressants for heart transplantation
Various advances in surgical techniques, especially organ transplants and the prevalence of severe coronary artery disease and dilated cardiomyopathy are leading to an increase in the need for heart transplantation surgeries. However, heart transplantation can lead to several types of heart transplant rejection such as acute cellular rejection, acute antibody rejection, and coronary artery vasculopathy chronic rejection. This is driving the need for heart transplantation therapeutics to prevent transplant rejection. Immunosuppressants are used to prevsent transplant rejection caused by immune system. Thus, the high dependency on immunosuppressants for heart transplantation will lead to the expansion of the global heart transplantation therapeutics market at a CAGR of almost 3% during the forecast period.

Advent of techniques for organ transplantation
The number of heart transplantation procedures is substantially high, especially in developed countries, due to the high prevalence of risk factors for heart impairment. Currently, the market is witnessing rapid development in the field of regenerative therapies, such as cell therapy, gene therapy, and tissue engineering, which also involve the development of heart and/or other organs. The introduction of novel approaches for heart regeneration and transplantation is one of the key heart transplantation therapeutics market trends. Organ printing is a modern technology, which is a layer-by-layer additive robotic bio-fabrication of 3D functional living macro tissues and organ constructs using tissue spheroids as building blocks. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of several major players, the global heart transplantation therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading heart transplantation therapeutics manufacturers, that include AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., F. Hoffmann-La Roche Ltd., Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Veloxis Pharmaceuticals A/S.

Also, the heart transplantation therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

Preface
Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem
Market characteristics
Market segmentation analysis

PART 04: MARKET SIZING

Market definition
Market sizing 2019
Market size and forecast 2019-2024
Market outlook

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product
Comparison by product
Immunosuppressants - Market size and forecast 2019-2024
Supplementary medications - Market size and forecast 2019-2024
Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation
Geographic comparison
North America - Market size and forecast 2019-2024
Europe - Market size and forecast 2019-2024
Asia - Market size and forecast 2019-2024
ROW - Market size and forecast 2019-2024
Key leading countries
Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers
Market challenges

PART 11: MARKET TRENDS

Advent of techniques for organ transplantation
Increasing strategic alliances
Growing international collaborations for organ transplantation

PART 12: VENDOR LANDSCAPE

Overview
Landscape disruption
Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered
Vendor classification
Market positioning of vendors
AbbVie Inc.
Astellas Pharma Inc.
Cadila Healthcare Ltd.
F. Hoffmann-La Roche Ltd.
Mylan NV
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Veloxis Pharmaceuticals A/S

PART 14: APPENDIX

Research methodology
List of abbreviations
Definition of market positioning of vendors

List of Exhibits

Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Vendor key offerings
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2019
Exhibit 18: Product - Market share 2019-2024 (%)
Exhibit 19: Comparison by product
Exhibit 20: Immunosuppressants - Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Immunosuppressants - Year-over-year growth 2020-2024 (%)
Exhibit 22: Supplementary medications - Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Supplementary medications - Year-over-year growth 2020-2024 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2019-2024 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2019-2024 ($ millions)
Exhibit 29: North America - Year-over-year growth 2020-2024 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2019-2024 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2020-2024 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Objectives of European Patients’ Forum
Exhibit 35: Asia - Market size and forecast 2019-2024 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2020-2024 (%)
Exhibit 37: Proportion of geriatric population in Asia 2009 and 2018 (% of total population)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2019-2024 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2020-2024 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Benefits of multiple dosage forms of drugs
Exhibit 45: Side effects of immunosuppressants
Exhibit 46: Demand-supply imbalance of organ transplantation 2011-2015
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: AbbVie Inc. - Vendor overview
Exhibit 54: AbbVie Inc. - Business segments
Exhibit 55: AbbVie Inc. - Organizational developments
Exhibit 56: AbbVie Inc. - Geographic focus
Exhibit 57: AbbVie Inc. - Key offerings
Exhibit 58: AbbVie Inc. - Key customers
Exhibit 59: Astellas Pharma Inc. - Vendor overview
Exhibit 60: Astellas Pharma Inc. - Business segments
Exhibit 61: Astellas Pharma Inc. - Organizational developments
Exhibit 62: Astellas Pharma Inc. - Geographic focus
Exhibit 63: Astellas Pharma Inc. - Key offerings
Exhibit 64: Astellas Pharma Inc. - Key customers
Exhibit 65: Cadila Healthcare Ltd. - Vendor overview
Exhibit 66: Cadila Healthcare Ltd. - Business segments
Exhibit 67: Cadila Healthcare Ltd. - Organizational developments
Exhibit 68: Cadila Healthcare Ltd. - Geographic focus
Exhibit 69: Cadila Healthcare Ltd. - Key offerings
Exhibit 70: Cadila Healthcare Ltd. - Key customers
Exhibit 71: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 72: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 73: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 74: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 75: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 76: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 77: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 78: Mylan NV - Vendor overview
Exhibit 79: Mylan NV - Business segments
Exhibit 80: Mylan NV - Organizational developments
Exhibit 81: Mylan NV - Geographic focus
Exhibit 82: Mylan NV - Segment focus
Exhibit 83: Mylan NV - Key offerings
Exhibit 84: Mylan NV - Key customers
Exhibit 85: Novartis AG - Vendor overview
Exhibit 86: Novartis AG - Business segments
Exhibit 87: Novartis AG - Organizational developments
Exhibit 88: Novartis AG - Geographic focus
Exhibit 89: Novartis AG - Segment focus
Exhibit 90: Novartis AG - Key offerings
Exhibit 91: Novartis AG - Key customers
Exhibit 92: Pfizer Inc. - Vendor overview
Exhibit 93: Pfizer Inc. - Business segments
Exhibit 94: Pfizer Inc. - Organizational developments
Exhibit 95: Pfizer Inc. - Geographic focus
Exhibit 96: Pfizer Inc. - Segment focus
Exhibit 97: Pfizer Inc. - Key offerings
Exhibit 98: Pfizer Inc. - Key customers
Exhibit 99: Sun Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 100: Sun Pharmaceutical Industries Ltd. - Business segments
Exhibit 101: Sun Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 102: Sun Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 103: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 104: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibit 105: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 106: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 107: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 108: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 109: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 111: Veloxis Pharmaceuticals A/S - Vendor overview
Exhibit 112: Veloxis Pharmaceuticals A/S - Business segments
Exhibit 113: Veloxis Pharmaceuticals A/S - Organizational developments
Exhibit 114: Veloxis Pharmaceuticals A/S - Geographic focus
Exhibit 115: Veloxis Pharmaceuticals A/S - Key offerings
Exhibit 116: Veloxis Pharmaceuticals A/S - Key customers
Exhibit 117: Validation techniques employed for market sizing
Exhibit 118: Definition of market positioning of vendors

Executive Summary

The following companies as the key players in the global heart transplantation therapeutics market: AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., F. Hoffmann-La Roche Ltd., Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Veloxis Pharmaceuticals A/S.

Commenting on the report, an analyst from research team said: “The latest trend gaining momentum in the market is the advent of techniques for organ transplantation.”

According to the report, one of the major drivers for this market is the high dependency on immunosuppressants for heart transplantation.

Further, the report states that one of the major factors hindering the growth of this market is the long-term complications associated with heart transplantation.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.